SCHEMBL4350458

SCHEMBL4350458

CCOc1ccc(F)cc1C(=O)c1cnc(N(C2CCNCC2)S(C)(=O)=O)nc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 11/20 0.48
CDK4 P11802 11/20 0.48
CCND1 P24385 11/20 0.48
CDK2 P24941 11/20 0.48
MRGPRX1 Q96LB2 7/20 0.41
TSPO P30536 2/20 0.41
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 1/20 0.39
HRH1 P35367 1/20 0.37
CASK O14936 1/20 0.36
ROCK2 O75116 1/20 0.36
CDKL5 O76039 1/20 0.36
STK10 O94804 1/20 0.36
CDK14 O94921 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
MAK P20794 1/20 0.36
CDK11B P21127 1/20 0.36
TTK P33981 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3517629 0.91 CDK1 (0.57) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4355674 0.89 CDK1 (0.55) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4357265 0.89 CDK1 (0.47) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4355978 0.89 CDK1 (0.55) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL5738145 0.89 CDK1 (0.55) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4352907 0.89 CDK1 (0.42) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4347303 0.87 CDK1 (0.44) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4352642 0.87 CDK1 (0.48) CDK1CDK4CCND1CDK2CASK
SCHEMBL4363543 0.86 CDK1 (0.54) CDK1CDK4CCND1CDK2SLC6A2
SCHEMBL4354198 0.86 CDK1 (0.57) CDK1CDK4CCND1CDK2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.